Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PHXMNASDAQ:SPRONASDAQ:VRCANASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/ASPROSpero Therapeutics$0.73+0.0%$0.74$0.51▼$1.72$40.54M0.64187,504 shs71,847 shsVRCAVerrica Pharmaceuticals$0.49+4.8%$0.56$0.38▼$11.41$44.89M1.68585,968 shs273,557 shsXLOXilio Therapeutics$0.83-1.1%$0.80$0.62▼$1.70$43.39M-0.251.18 million shs125,027 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%SPROSpero Therapeutics0.00%-3.85%-15.68%-16.42%-48.93%VRCAVerrica Pharmaceuticals0.00%-0.29%+11.79%-32.33%-92.80%XLOXilio Therapeutics0.00%+10.23%+13.51%+1.02%-21.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASPROSpero Therapeutics4.3172 of 5 stars3.32.00.04.72.50.82.5VRCAVerrica Pharmaceuticals4.0979 of 5 stars3.12.00.04.72.73.30.6XLOXilio Therapeutics3.1043 of 5 stars3.55.00.00.02.20.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePHXMPHAXIAM Therapeutics 0.00N/AN/AN/ASPROSpero Therapeutics 2.50Moderate Buy$5.00589.46% UpsideVRCAVerrica Pharmaceuticals 2.20Hold$9.501,842.34% UpsideXLOXilio Therapeutics 3.00Buy$4.00382.80% UpsideCurrent Analyst Ratings BreakdownLatest PHXM, VRCA, XLO, and SPRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/8/2025VRCAVerrica PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/12/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold1/30/2025SPROSpero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPHXMPHAXIAM Therapeutics$32.66M0.32N/AN/A$7.98 per share0.39SPROSpero Therapeutics$27.40M1.48$0.45 per share1.62$2.02 per share0.36VRCAVerrica Pharmaceuticals$7.57M5.93N/AN/A$0.47 per share1.04XLOXilio Therapeutics$6.34M6.76N/AN/A$1.34 per share0.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/ASPROSpero Therapeutics$22.81M-$1.2710.36N/AN/A3.30%4.03%2.21%5/13/2025 (Estimated)VRCAVerrica Pharmaceuticals-$67M-$1.54N/AN/AN/A-625.06%-591.84%-141.63%5/12/2025 (Estimated)XLOXilio Therapeutics-$76.40M-$1.28N/AN/AN/AN/A-211.50%-80.31%5/13/2025 (Estimated)Latest PHXM, VRCA, XLO, and SPRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025SPROSpero Therapeutics-$0.44N/AN/AN/AN/AN/A5/13/2025Q1 2025XLOXilio Therapeutics$0.10N/AN/AN/AN/AN/A5/12/2025Q1 2025VRCAVerrica Pharmaceuticals-$0.10N/AN/AN/A$2.53 millionN/A3/27/2025Q4 2024SPROSpero Therapeutics-$0.35-$0.38-$0.03-$0.38$12.40 million$15.04 million3/11/2025Q4 2024VRCAVerrica Pharmaceuticals-$0.25-$0.24+$0.01-$0.24$1.30 million$0.34 million3/11/2025Q4 2024XLOXilio Therapeutics-$0.22-$0.20+$0.02-$0.20$2.26 million$1.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ASPROSpero Therapeutics$0.068.27%N/AN/A N/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPHXMPHAXIAM Therapeutics0.231.78N/ASPROSpero TherapeuticsN/A2.682.68VRCAVerrica PharmaceuticalsN/A1.341.22XLOXilio TherapeuticsN/A1.671.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPHXMPHAXIAM Therapeutics0.40%SPROSpero Therapeutics25.60%VRCAVerrica Pharmaceuticals42.45%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipPHXMPHAXIAM Therapeutics1.94%SPROSpero Therapeutics4.52%VRCAVerrica Pharmaceuticals42.60%XLOXilio Therapeutics5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataSPROSpero Therapeutics15055.90 million52.05 millionOptionableVRCAVerrica Pharmaceuticals4091.78 million26.18 millionOptionableXLOXilio Therapeutics7051.78 million41.67 millionNot OptionablePHXM, VRCA, XLO, and SPRO HeadlinesRecent News About These CompaniesXilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual MeetingApril 23, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comXilio Therapeutics reports Q4 EPS (20c) vs (64c) last yearMarch 11, 2025 | markets.businessinsider.comXilio Therapeutics files $250M mixed securities shelfMarch 11, 2025 | markets.businessinsider.comXilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue EstimatesMarch 11, 2025 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | globenewswire.comXilio Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | globenewswire.comXilio Therapeutics, Inc.: Xilio Therapeutics Announces Multiple Masked T Cell Engager ProgramsFebruary 12, 2025 | finanznachrichten.deXilio Therapeutics Shares Surge Premarket on AbbVie DealFebruary 12, 2025 | marketwatch.comAbbVie, Xilio Hook upFebruary 12, 2025 | baystreet.caAbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager dealFebruary 12, 2025 | fiercebiotech.comAbbVie expands oncology R&D with Xilio dealFebruary 12, 2025 | thepharmaletter.comXilio Therapeutics Announces Multiple Masked T Cell Engager ProgramsFebruary 12, 2025 | globenewswire.comAbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated ImmunotherapiesFebruary 12, 2025 | globenewswire.comAbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated ImmunotherapiesFebruary 12, 2025 | prnewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 3, 2025 | globenewswire.comXilio shares tumble after mixed vilastobart dataJanuary 24, 2025 | thepharmaletter.comWhy Did Chardan Capital Markets Give Xilio Therapeutics Inc (XLO) Stock Buy Rating?January 24, 2025 | bovnews.comXilio reports results from ongoing Phase 2 clinical trial of vilastobartJanuary 23, 2025 | markets.businessinsider.comXilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal CancerJanuary 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHXM, VRCA, XLO, and SPRO Company DescriptionsPHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 04/25/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Spero Therapeutics NASDAQ:SPRO$0.73 +0.00 (+0.03%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.72 -0.01 (-0.72%) As of 04/25/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Verrica Pharmaceuticals NASDAQ:VRCA$0.49 +0.02 (+4.84%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.50 +0.02 (+3.25%) As of 04/25/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.Xilio Therapeutics NASDAQ:XLO$0.83 -0.01 (-1.13%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.82 -0.01 (-1.51%) As of 04/25/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
